Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RO7200220 plus ranibizumab in diabetic macular edema
2021-004390-31Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vamikibart and ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Roche. Primary endpoint: Change in best corrected visual acuity (BCVA). Started Feb 2022; status: completed.
02
Drugs
vamikibartranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2021-004390-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004390-31.